Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lori A Leslie

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Current Treatment Options in Oncology|October 25, 2021
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin LymphomasLori A Leslie
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Clinical use of emerging therapies in relapsed or refractory follicular lymphomaLori A Leslie
Leukemia & Lymphoma|February 28, 2013
Targeting oncogenic and epigenetic survival pathways in lymphomaLori A Leslie, Anas Younes
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Antibody-drug conjugates in hematologic malignanciesLori A Leslie, Anas Younes
Health Physics|March 7, 2023
Radon-222 and LeukemiaNaomi H Harley, Lori A Leslie
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Refining the management of relapsed or refractory follicular lymphoma: case scenariosJohn M Pagel, John M Burke, Lori A Leslie
Current Medical Research and Opinion|October 7, 2022
Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemiaLori A Leslie, Nilesh Gangan, Hiangkiat Tan, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Refining the management of relapsed or refractory follicular lymphomaJohn M Pagel, John M Burke, Lori A Leslie
Advances in Therapy|May 24, 2022
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk StatusQing Huang, Kathleen L Deering, Qing Harshaw, et al.
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
How often do hematologists consider celiac disease in iron-deficiency anemia? Results of a national surveyScott Smukalla, Benjamin Lebwohl, J Gregory Mears, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Current Treatment Options in Oncology|October 25, 2021
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin LymphomasLori A Leslie
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Clinical use of emerging therapies in relapsed or refractory follicular lymphomaLori A Leslie
Leukemia & Lymphoma|February 28, 2013
Targeting oncogenic and epigenetic survival pathways in lymphomaLori A Leslie, Anas Younes
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Antibody-drug conjugates in hematologic malignanciesLori A Leslie, Anas Younes
Health Physics|March 7, 2023
Radon-222 and LeukemiaNaomi H Harley, Lori A Leslie
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Refining the management of relapsed or refractory follicular lymphoma: case scenariosJohn M Pagel, John M Burke, Lori A Leslie
Current Medical Research and Opinion|October 7, 2022
Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemiaLori A Leslie, Nilesh Gangan, Hiangkiat Tan, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Refining the management of relapsed or refractory follicular lymphomaJohn M Pagel, John M Burke, Lori A Leslie
Advances in Therapy|May 24, 2022
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk StatusQing Huang, Kathleen L Deering, Qing Harshaw, et al.
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
How often do hematologists consider celiac disease in iron-deficiency anemia? Results of a national surveyScott Smukalla, Benjamin Lebwohl, J Gregory Mears, et al.
Pageof 5